Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) announced that on April 20, 2026 the Compensation Committee approved an inducement award of 7,094 restricted stock units (RSUs) for a newly hired employee under its 2021 Inducement Award Plan.
The RSUs vest in substantially equal annual installments on each of the first three anniversaries of the employee’s start date, subject to continued service.
Precision BioSciences (NASDAQ: DTIL) will present late-breaking biopsy data for PBGENE-HBV at EASL Congress 2026, showing evidence of elimination and inactivation of cccDNA in liver biopsies from the ongoing Phase 1 ELIMINATE-B trial.
The poster (LB26-51656 / LBP-043) will be presented by Man-Fung Yuen on May 27, 2026 at 8:30 CEST in Barcelona.
Precision BioSciences (Nasdaq: DTIL) received Clinical Trial Application approvals to expand the global ELIMINATE-B trial into France and Romania, adding European sites to existing locations in the UK, Moldova, New Zealand, Hong Kong and the US. Site initiation activities are underway and initial patient screening is expected in Q2 2026.
The expansion aims to support continued patient enrollment and clinical execution of PBGENE-HBV, a gene editing therapy designed to eliminate cccDNA, as the company advances the ELIMINATE-B trial.
Precision BioSciences (Nasdaq: DTIL) will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 9:30am ET. The presentation is virtual and will be webcast. A replay will be posted in the company's Investors section under Events and Presentations after the event.
If investors or analysts wish to request a meeting, contact your Needham representative.
iECURE (NASDAQ:DTIL) announced that ECUR-506, its investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, was selected for the FDA’s CMC Development and Readiness Pilot (CDRP) program.
Participation enables more frequent FDA engagement on CMC strategy ahead of a potential BLA, complements prior RMAT and Fast Track designations, and follows encouraging OTC-HOPE clinical data including a complete response in the first treated infant. Additional trial data is expected in H1 2026.
Precision BioSciences (Nasdaq: DTIL) reported Q4 and FY2025 results and provided clinical and corporate updates. Key highlights include PBGENE-HBV Phase 1 late-breaker data showing safety and dose-dependent antiviral activity, IND clearance for PBGENE-DMD in Feb 2026, and a $75M financing in Nov 2025.
The company ended 2025 with $137.2M cash, expects runway through 2028, reported Q4 revenue of $34.2M and full-year revenue of $34.3M, and received two patent Notices of Allowance extending PBGENE-HBV protection to Nov 2044.
Precision BioSciences (Nasdaq: DTIL) received two U.S. Notices of Allowance for patent applications covering its PBGENE-HBV program, including composition-of-matter claims for the PBGENE-HBV ARCUS nuclease and a novel shortened polypeptide linker.
When issued, each patent is expected to expire in November 2044, extending intellectual property protection for PBGENE-HBV and future ARCUS nucleases that use the linker.
Precision BioSciences (Nasdaq: DTIL) presented preclinical GLP data for PBGENE-DMD at the MDA Clinical & Scientific Conference 2026 showing durable dystrophin restoration and sustained functional benefit in a humanized DMD mouse model. Data include 50–65% reduction in CK at 90 days and sustained force output through nine months.
Findings report broad dystrophin-positive fibers in quadriceps, gastrocnemius, heart, and diaphragm and evidence of edited muscle satellite cells, supporting a one-time in vivo gene correction approach potentially applicable to ~60% of DMD patients.
Precision BioSciences (Nasdaq: DTIL) will publish fourth-quarter and fiscal 2025 financial results and deliver a business update on March 12, 2026. The company develops in vivo gene editing therapies using its proprietary ARCUS platform for high unmet-need diseases. Investors can expect results and management commentary on that date.
Precision BioSciences (Nasdaq: DTIL) announced the U.S. FDA granted Fast Track designation to PBGENE-DMD for treating Duchenne muscular dystrophy (DMD) and that it will host a virtual investor/KOL event on March 17, 2026 to discuss PBGENE-DMD and the planned Phase 1/2 FUNCTION-DMD study.
The company said Fast Track aims to facilitate development and expedite review, and noted recent IND clearance supporting PBGENE-DMD’s advancement toward clinical investigation in boys living with DMD.